[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymph-node-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymph-node-disease":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100542265","eus-examination-using-endosound-vision-system-vs-standard-echoendoscope-100542265",false,"NCT06340620","EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope","Randomized Trial of Endoscopic Ultrasound Examination Using EndoSound Vision System vs. Standard Echoendoscope","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Unable to obtain consent for the procedure from either the patient or LAR.\n* Intrauterine pregnancy.","ALL","18 Years","100 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.",[27,28,29,30,31,32,33,34,35],"Pancreatic Disease","Pancreatic Cancer","Pancreatic Cyst","Gastrointestinal Tumor","Bile Duct Diseases","Bile Duct Cancer","Lymph Node Disease","Submucosal Tumor of Gastrointestinal Tract","Gastrointestinal Cancer",[37,38,39],"Endoscopic ultrasound","EndoSound Vision System","Randomized trial","RECRUITING","2024-03-25",{"date":43,"type":44},"2024-04-01","ACTUAL",{"date":41,"type":21},{"date":47,"type":21},"2027-12",{"name":49,"class":50},"Orlando Health, Inc.","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100519915","d2-versus-d3-dissection-in-laparoscopic-right-hemicolectomy-100519915","NCT06049758","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy In Right Cancer Colon Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with right-side colon cancer (caecum, ascending, or hepatic flexure)\n* Diagnosed by CT entero-colonography\n* Diagnosed by colonoscopy\n* Diagnosed by biopsy.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction, perforation with generalized peritonitis),\n* Metastatic tumor diagnosed\n* ASA score of IV or higher\n* Need for more than one surgical procedure\n* Conversion to open surgery",true,{"count":61,"type":21},80,[24],"Evaluating the differences between D2 and D3 lymphadenectomy in laparoscopic right hemicolectomy in patients with right cancer colon post-operative outcome, intra-operative blood transfusion, post-operative ICU admission, anastomotic leakage, lymph node harvesting in the final specimen, and six months follow up and overall survival time after 5-years",[65,66,67,33,68,69],"Blood Loss","Intensive Care","Anastomotic Leakage","Survival","Blood Transfusion","NOT_YET_RECRUITING","2023-09-19",{"date":73,"type":44},"2023-09-22",{"date":75,"type":21},"2024-01-02",{"date":77,"type":21},"2030-01-02",{"name":79,"class":80},"General Committee of Teaching Hospitals and Institutes, Egypt","OTHER_GOV",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":105,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":51},"100393503","the-role-of-micrometastasis-and-isolated-tumor-cells-itcs-in-endometrial-and-cervical-cancer-a-multicenter-study-100393503","NCT04403867","The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.","The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Uterine Cancers (Endometrial\u002FCervical) Submitted to Sentinel Lymph Nodes (SLN) Procedure: an Observational Study","ITCMicroUtCa","Inclusion Criteria:\n\n* Early stage endometrial cancer scheduled for SLN procedure\n* Early stage cervical cancer scheduled for SLN procedure\n* Pathological evaluation of SLNs with standard ultra-staging or one-step nucleic acid amplification (OSNA) for the detection of metastasis\n* Presence of lymph nodes metastasis (macrometastasis or low volume disease \\[micrometastasis and isolated tumor cells\\])\n\nExclusion Criteria:\n\n* Previous (\\\u003C5 years) or concomitant malignancy other than non-melanoma skin cancer\n* Advanced\u002Fmetastatic endometrial cancer\n* Locally advanced\u002Fmetastatic cervical cancer","FEMALE",{"count":91,"type":21},500,"OBSERVATIONAL","The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined.\n\nThis study was designed to create a dataset of patients with lymph nodal disease. Data on type and volume of lymph nodal disease, therapeutic choices and oncological outcomes (DFS, OS, recurrence rate) will be collected and analyzed.\n\nThis will allow to define the groups of patients who may need or for whom it can be avoided any adjuvant treatment on the basis of lymph node status.",[95,96,97,98,99,100,101,102,103,104,33],"Endometrial Cancer","Cervical Cancer","Sentinel Lymph Node","Micrometastasis","Sentinel Lymph Node Biopsy","Endometrium Tumor","Endometrial Neoplasms","Cervical Neoplasm","Cervical Tumor","Lymph Node Metastases",[106,107,108,109,110,111,112,113,114,115,116,117],"endometrial cancer","cervical cancer","sentinel lymph node","low volume disease","survival","recurrence rate","adjuvant therapy","micrometastases","isolated tumor cell","macrometastases","ultrastaging","one-step nucleic acid amplification (OSNA)","2022-08-15",{"date":120,"type":44},"2022-08-17",{"date":122,"type":44},"2020-01-02",{"date":124,"type":21},"2027-01",{"name":126,"class":50},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"]